![]() |
| During a Convention Center network outage, OncoLink saves the day! |
|
A Multicenter Randomized Phase III Study Comparing Paclitaxel-Cisplatin-Etoposide (TEP) Versus Cisplatin-Etoposide (EP) as Front - Line Treatment in Patients with Small Cell Lung Cancer (SCLC)
Presenter: Dimitrios Mavroudis Affiliation: The Greek Lung Cancer Cooperative Group Background: The combination of etoposide (E) and cisplatin (P) is standard first line treatment for small cell lung cancer (SLSC). A complete response ... |
|
|
A Phase III Trial of the Use of Long Term Androgen Suppression Following Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate.
Presenter: Gerald E. Hanks Affiliation: Fox Chase Cancer Center Background: Radiation therapy is a long-standing treatment option for prostate cancer Previous studies by the RTOG and the EORTC have demonstrated improved disease-specific... |
|
|
A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
Presenter: Joan H. Schulter Affiliation: ECOG Background: Since the initial randomized trials in the early 1990's which showed improved median and overall survival by adding chemotherapy to radiation therapy (RT) in NSCLC patients,... |
|
|
A Randomized Trial Comparing Two Fractionation Schedules for Breast
Irradiation Postlumpectomy in Node-Negative Breast Cancer
Presenter: Timothy J. Whelan Affiliation: Hamilton Regional Cancer Ctr, Hamilton, ON, Canada; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; McMaster Univ, Hamilton, ON, Canada; Kingston Regional Cancer Ctr, Kingston, ON,... |
|
|
Comparison of health-related quality of life (HRQOL) after brachytherapy, radical prostatectomy, or external beam radiation for localized prostate cancer
Presenter: M.G. Sanda Affiliation: University of Michigan Background: Many oncologists believe that in selected patients, the differences between disease free survival and overall survival for radical prostatectomy (RP), external beam... |
|
|
Cytoreduction Nephrectomy in Metastatic Renal Cancer: The Results of
Southwest Oncology Group Trial 8949
Presenter: Robert Charles Flanigan Affiliation: Southwest Oncology Group Background: Metastatic renal cancer has a poor prognisis and is classically highly resistant to chemotherapy. A number of case series have reported a benefit to... |
|
|
Postoperative Combined Radiation and Chemotherapy Improves Disease-Free
Survival (DFS) and Overall Survival (OS) in Resected Adenocarcinoma of
the Stomach and G.E. Junction. Results of Intergroup Study INT-0116
(SWOG 9008)
Presenter: John S. Macdonald Affiliation: SWOG; ECOG; RTOG; CALGB; NCCTG Background: It is estimated that there will be 22,000 new cases and 13,500 deaths from gastric cancer in the US this year. The cure rate for gastric carcinoma... |
|
|
Topotecan (T) vs. Observation (OB) Following Cisplatin (P) Plus Etoposide (E) in Extensive Stage Small Cell Lung Cancer (ES SCLC) (E7593): A Phase III Trial of the Eastern Cooperative Oncology Group (ECOG)
Presenter: D. H. Johnson Affiliation: Vanderbilt University Background: Topotecan, a topoisomerase I inhibitor, has a 40% response rate as a first line agent in SCLC and moderate activity in chemoresistant SCLC. This Phase III trial... |
|
|
Venlafaxine Alleviates Hot Flashes: An NCCTG Trial
Presenter: Charles L Loprinzi Affiliation: North Central Cancer Treatment Group, Rochester, MN Background: Hot flashes can be a significant problem for many cancer patients. Unconventional treatments such as vitamin E and soy have been shown... |